the aid library

LIST OPTIONS

Filter

5940

Global Strategy for Asthma Management and Prevention (2022 update)

Global Initiative for Asthma (2022) CC2

The reader acknowledges that this report is intended as an evidence-based asthma management strategy, for the use of health professionals and policy-makers. It is based, to the best of our knowledge, on current best evidence and medical knowledge and practice at the date of publication. When assessi... more

External Link

Antimicrobial resistance and the nurse’s role

Agne Diminskyte (2016) C2

Antimicrobial resistance is a global threat as it is present in all parts of the world and it means that there is a shortage of effective antibiotics to treat simple infections and diseases, also statistics reveal that because of antimicrobial resistance patients’ morbidity and mortality is increa... more

Download (601)

View PDF (744)

A8 e-Therapy using computer and mobile technologies in treatment

Karolina Stasiak & Sally Merry IACAPAP (2015) C2

This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws o... more

Download (1770)

View PDF (2019)

WHO compendium of innovative health technologies for low-resource settings, 2021: COVID-19 and other health priorities
recommended

World Health Organization WHO (2022) C_WHO

The objective of the 2022 Compendium is to compile and highlight emerging innovative health technologies for low-resource settings. It presents a snapshot of technologies that are solutions to an unmet medical/health technology need or are likely to improve health outcomes and the quality of life. H... more

Download (447)

View PDF (679)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (174)

View PDF (302)

Improving the global diagnosis and management of asthma in children

Lenney, W.; Bush, A.; Fitzgerald, D.A. et al. BMJ Journals (2018) CC

Asthma is the most common chronic condition in children worldwide. It affects daytime activities, sleep and school attendance and causes anxiety to parents, families and other carers. The quality of asthma diagnosis and management globally still needs substantial improvement. From infancy to the tee... more

Download (351)

View PDF (377)

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Download (373)

View PDF (335)

Psychological interventions in adults and children with epilepsy

World Health Organization WHO (2012) C_WHO

Q 10: In adults and children with epilepsy, which psychological interventions used as adjunctive therapies with antiepileptic drugs when compared to placebo/comparator produce benefits/harm in specified outcomes?

Download (1028)

View PDF (1720)

Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults

World Health Organization WHO (2014) C_WHO

Skin and mucosal conditions are extremely common in all children and adults in particular in HIV-infected adults and children and are one of the commonest daily management problems faced by health care workers caring for patients with HIV infection

Download (289)

View PDF (279)

Заболевание COVID-19 у детей и подростков Научная справка 29 сентября 2021 г.

World Health Organization WHO (2021) C_WHO

SARS-CoV-2 infections among children and adolescents cause less severe illness and fewer deaths compared to adults. While a less severe course of infection is a positive outcome, there are concerns that mild symptoms may have led to less testing, resulting in fewer identified cases of COVID-19 in ch... more

Download (1697)

View PDF (2047)

PIH Guide to the Medical Management of MDR-TB

USAID; TB Care; DRTB Training Network (2014) C1

This guide is a resource for physicians and other health care professionals who provide care and treatment to patients with drug-resistant tuberculosis.

Download (453)

View PDF (437)

Guidance for commissioners of older people’s mental health services

Joint Commissioning Panelfor Mental Health (2013) C2

This guide has been written to provide information and practical advice on developing and delivering local plans an strategies to commission the most effective and efficient older people’s mental health services.Based upon clinical best practice guidance and drawing upon the range of available evi... more

Download (393)

View PDF (423)

Clinical management and infection prevention and control for monkeypox
recommended

World Health Organization WHO (2022) C_WHO

Interim rapid response guidance, 10 June 2022. It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons... more

External Link

Financing HIV Programming: How Much Should Low And Middle-Income Countries and their Donors Pay?

Galarraga, O.; V. J. Wirtz; Y. Santa-Ana-Tellez et al. PLOS One (2013) C1

Global HIV control funding falls short of need. To maximize health outcomes, it is critical that national governments sustain reasonable commitments, and that international donor assistance be distributed according to country needs and funding gaps. We develop a country classification framework in t... more

Download (735)

View PDF (622)

Hypertension Management Program (HMP) Toolkit

Centers for Disease Control and Prevention (CDC) (2021) C_CDC

This toolkit was developed by the Centers for Disease Control and Prevention (CDC) Division for Heart Disease and Stroke Prevention (DHDSP) to provide healthcare organizations, including those in resource-constrained settings, with the information and resources to implement the HMP and improve hyper... more

Download (259)

View PDF (390)

Communicable Diseases: Part 4 Other Diseases of Public Health Importance and Surveillance.

HEAT, UNICEF, Open University, AMREF Ministry of Health, Federal Democratic Republic of Ethiopia (2015) C1

Blended Learning Modulef or the Health Extension Programme In this study session, you will learn about the general features of faeco-oraldiseases: the main types commonly found in Ethiopia, their general symptomsand signs, how to treat mild cases and when to refer patients with severeconditions for... more

Download (214)

View PDF (177)

Monitoring asthma in children

Pijnenburg, M.W.; Baraldi, E.; Brand, P.L. et al. European Respiratory Journal (2015) CC

The goal of asthma treatment is to obtain clinical control and reduce future risks to the patient. To reach this goal in children with asthma, ongoing monitoring is essential. While all components of asthma, such as symptoms, lung function, bronchial hyperresponsiveness and inflammation, may exist i... more

Download (750)

View PDF (1016)

Second WHO Model List of Essential In Vitro Diagnostics

World Health Organization WHO (2019) C_WHO

The updated List of Essential Diagnostics contains 46 general tests that can be used for routine patient care as well as for the detection and diagnosis of a wide array of disease conditions, and 69 tests intended for the detection, diagnosis and monitoring of specific diseases. The List is divid... more

Download (339)

View PDF (290)

Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial

Pohlig G, Bernhard SC, Blum J, Burri C, Mpanya A, et al. PLOS Neclected Tropical Diseases (2016) CC

This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita... more

Download (223)

View PDF (262)

Rehabilitation considerations during the COVID-19 outbreak

Pan American Health Organization PAHO, World Health Organization WHO (2020) C_WHO

Severe cases of COVID-19 are associated with rehabilitation needs related to the consequences of ventilatory support, and prolonged immobilization and bed rest. These may include: − Impaired lung function; − Physical deconditioning and muscle weakness; − Delirium and other cognitive impairment... more

WHO compendium of innovative health technologies for low-resource settings, 2021: COVID-19 and other health priorities recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022 recommended

Clinical management and infection prevention and control for monkeypox recommended

WHO compendium of innovative health technologies for low-resource settings, 2021: COVID-19 and other health priorities
recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

Clinical management and infection prevention and control for monkeypox
recommended